Bain Capital Life Sciences's book
17 companies · priced by our data| Company | Industry | Valuation | $/share | First invested | Role |
|---|---|---|---|---|---|
| Freenome | Decision/Risk Analysis | $2.2B | — | — | |
| Imperative Care | Surgical Devices | $1.6B | — | — | |
| HeartFlow (NAS: HTFL) | Decision/Risk Analysis | $1.5B | — | — | |
| Kailera Therapeutics (NAS: KLRA) | — | $1.5B | — | — | |
| Areteia Therapeutics | Drug Discovery | $1.3B | — | — | |
| Cardurion | Biotechnology | $760.0M | — | — | |
| Abcuro | Drug Discovery | $700.0M | — | — | |
| Avistone Pharmaceuticals Biotechnology | — | $628.3M | — | — | |
| Synthekine | — | $500.0M | — | — | |
| Rivus Pharmaceuticals | Drug Discovery | $489.0M | — | — | |
| + 7 more companies · a free account shows the top 25 | |||||
Free account
See the whole book
- ·The book's top 25 — of 17 recorded positions
- ·Watchlist + alerts for Bain Capital Life Sciences's activity
Create free account
No card required